Picture loading failed.

Anti-IGF1R therapeutic antibody (Pre-made Cixutumumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cixutumumab (IMC-A12) is a human monoclonal antibody for the treatment of solid tumors.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-108-1mg 1mg 3090
GMP-Bios-ab-108-10mg 10mg 21890
GMP-Bios-ab-108-100mg 100mg 148000
GMP-Bios-ab-108-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-IGF1R therapeutic antibody (Pre-made Cixutumumab biosimilar,Whole mAb)
INN Name Cixutumumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2008
Year Recommended2009
CompaniesEli Lilly;ImClone Systems;M. D. Anderson Cancer Center;National Cancer Institute (USA)
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedBreast cancer;Colorectal cancer;Head and neck cancer;Liver cancer;Neuroendocrine tumours;Non-small cell lung cancer;Oesophageal cancer;Pancreatic cancer;Prostate cancer;Rhabdomyosarcoma;Sarcoma;Soft tissue sarcoma;Solid tumours;Thymoma
Development TechDyax Human Phage Display